Related Experiment Videos
Lipid disorders and mutations in the APOB gene
Amanda J Whitfield1, P Hugh R Barrett, Frank M van Bockxmeer
1School of Surgery and Pathology, University of Western Australia, Crawley.
Clinical Chemistry
|August 17, 2004
Summary
Genetic defects in apolipoprotein B (apoB) metabolism can cause familial hypobetalipoproteinemia or familial ligand-defective apoB-100, impacting cholesterol levels and atherosclerosis risk.
Area of Science:
- Biochemistry
- Genetics
- Metabolic pathways
Background:
- Plasma lipoproteins are key factors in atherosclerosis development.
- Apolipoprotein B (apoB) is crucial for lipoprotein metabolism, with two forms (apoB-48 and apoB-100) produced from the APOB gene.
- ApoB-100 serves as the ligand for LDL receptor-mediated endocytosis.
Purpose of the Study:
- To review the regulation of apoB metabolism.
- To examine how APOB gene defects lead to hypo- and hypercholesterolemia.
- To describe the clinical, metabolic, and genetic features of specific dyslipidemias.
Main Methods:
- Review of existing literature on monogenic dyslipidemias.
- Analysis of APOB gene mutations and their effects on apoB metabolism.
- Description of clinical and genetic characteristics of familial hypobetalipoproteinemia and familial ligand-defective apoB-100.
Main Results:
- Missense mutations in the LDL-receptor-binding domain of apoB result in familial ligand-defective apoB-100, causing hypercholesterolemia and early coronary artery disease.
- Other APOB mutations lead to familial hypobetalipoproteinemia, characterized by hypocholesterolemia and atherosclerosis resistance.
- Naturally occurring mutations highlight critical apoB domains and their roles in lipid metabolism.
Conclusions:
- Monogenic dyslipidemias offer insights into biologically significant mechanisms.
- APOB gene mutations demonstrate the link between apoB structure/function and lipid disorders.
- Understanding these mutations aids in comprehending lipoprotein metabolism and associated diseases.